Clinical Trial Detail

NCT ID NCT03893955
Title A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors AbbVie
Indications

lung non-small cell carcinoma

Advanced Solid Tumor

triple-receptor negative breast cancer

Therapies

ABBV-368 + ABBV-927 + Nab-paclitaxel

ABBV-368 + ABBV-927

ABBV-181 + ABBV-368 + ABBV-927

ABBV-181 + ABBV-927 + Carboplatin

ABBV-927 + Carboplatin

ABBV-368 + ABBV-927 + Carboplatin

Age Groups: adult senior

No variant requirements are available.